N-(Cbz)-N'-(t-Boc)-guanidine | 194985-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(Cbz)-N'-(t-Boc)-guanidine
• 英文别名: N-Boc-N'-Cbz-guanidine；benzyl N-[N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate
• CAS: 194985-14-3
• 化学式: C₁₄H₁₉N₃O₄
• 分子量: 293.323
• InChiKey: HXXLPXYJKOPUDG-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(Cbz)-N'-(t-Boc)-guanidine 在 palladium on charcoal 、 钯 盐酸 作用下， 以 甲醇 为溶剂， 生成 N-(t-Boc)-guanidine hydrochloride
  参考文献：
  名称：

  Serine protease inhibitors

  摘要：

  本发明涉及一种具有式（I）的化合物，其中A、B、X、N、Z和Q的定义如描述中所述。本发明的化合物具有抗凝活性，可用于治疗或预防与凝血酶相关的疾病。##STR1##

  公开号：

  US06034067A1
• 作为产物：
  描述：

  N-(tert-butoxycarbonyl)-N′-(benzyloxycarbonyl)-S-methylisothiourea 以 methanolic ammonia 为溶剂， 生成 N-(Cbz)-N'-(t-Boc)-guanidine
  参考文献：
  名称：

  Serine protease inhibitors

  摘要：

  本发明涉及一种具有式（I）的化合物，其中A、B、X、N、Z和Q的定义如描述中所述。本发明的化合物具有抗凝活性，可用于治疗或预防与凝血酶相关的疾病。##STR1##

  公开号：

  US06034067A1

文献信息

• Guanidinylation reagents
  申请人：The Regents of the University of California

  公开号：US06072075A1

  公开（公告）日：2000-06-06

  Trisubstituted N-protected guanidines and methods for use as guanidinylating reagents to yield N-protected guanidine derivatives.

  三取代N-保护胍和用作胍基化试剂以产生N-保护胍基衍生物的方法。
• <i>N</i>^G-Acylated Imidazolylpropylguanidines as Potent Histamine H₄ Receptor Agonists: Selectivity by Variation of the <i>N</i>^G-Substituent
  作者：Patrick Igel、Erich Schneider、David Schnell、Sigurd Elz、Roland Seifert、Armin Buschauer

  DOI：10.1021/jm9000693

  日期：2009.4.23

  3-(1H-Imidazol-4-yl)propylguanidine (SK&F 91486, 4) was identified as a potent partial agonist at the human histamine H-3 receptor (hH(3)R) and human histamine H-4 receptor (hH(4)R). With the aim to increase selectivity for the hH4R, the guanidine group in 4 was acylated. N-1-Acetyl-N-2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-PI288, 13) was a potent full agonist at the hH(4)R (pEC(50) = 8.31; alpha = 1.00), possessing more than 1000- and 100-fold selectivity relative to the hH(1)R and hH(2)R, respectively, and possessing only low intrinsic activity (alpha = 0.27) at the hH(3)R.
• Palladium- or Iridium-Catalyzed Allylic Substitution of Guanidines: Convenient and Direct Modification of Guanidines
  作者：Hideto Miyabe、Kazumasa Yoshida、Valluru Krishna Reddy、Yoshiji Takemoto

  DOI：10.1021/jo802271d

  日期：2009.1.2

  As a convenient and direct functionalization of guanidines, the transition metal-catalyzed allylic substitution of guanidines was studied. The guanidine derivatives bearing two electron-withdrawing substituents acted as reactive nucleophiles in the allylic substitution to give the rnonoallylated products. The double allylic substitution was achieved by using tri-Boc-guanidine bearing three electron-withdrawing substituents as a nucleophile to give the diallylated products. The regiocontrol in the allylic substitution of unsymmetrical allylic substrates has been investigated by employing the palladium or iridium catalysts. The iridium complex of chiral pybox ligand allowed the regio- and enantioselective allylic substitution. Asymmetric double allylic substitution of tri-Boc-guanidine with phosphate bearing the 1-naphthyl group gave the diallylated product with high diastereo-, regio-, and enantioselectivities.
• SERINE PROTEASE INHIBITORS
  申请人：Akzo Nobel N.V.

  公开号：EP1007544A1

  公开（公告）日：2000-06-14
• US6034067A
  申请人：——

  公开号：US6034067A

  公开（公告）日：2000-03-07